PYC Physiomics Plc

TIDMPYC

Physiomics PLC

04 August 2023

4 August 2023

Physiomics plc

("Physiomics") or ("the Company")

Contract award

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Bicycle Therapeutics ("Bicycle") that it expects to be completed over the next six months. The project involves modelling and the use of bioinformatics data in support of target identification for undisclosed Bicycle programs.

Physiomics CEO, Dr Jim Millen, commented: "We are delighted that, having worked on a number of clinical stage projects with Bicycle, we are now complementing these with a substantial project focused on earlier stage drug development. We look forward to working once again with Bicycle's talented team."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies. Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 projects, over 40 targets and 70 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUPUUGRUPWGMW

(END) Dow Jones Newswires

August 04, 2023 02:00 ET (06:00 GMT)

Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024